Cargando…

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model

BACKGROUND: Dysregulation of the Src pathway has been shown to be important at various stages of cancer. Dasatinib is a potent Src/Abl inhibitor and has demonstrated to have anti-proliferative and anti-invasive activity in many preclinical models. The objective of this study was to determine the ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scott, Aaron J., Song, Eun-Kee, Bagby, Stacey, Purkey, Alicia, McCarter, Martin, Gajdos, Csaba, Quackenbush, Kevin S., Cross, Benjamin, Pitts, Todd M., Tan, Aik Choon, Eckhardt, S. Gail, Fenton, Hubert, Arcaroli, John, Messersmith, Wells A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665512/ https://www.ncbi.nlm.nih.gov/pubmed/29091939 http://dx.doi.org/10.1371/journal.pone.0187173

Ejemplares similares

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
por: Arcaroli, J J, et al.
Publicado: (2013)

Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
por: Pitts, Todd M., et al.
Publicado: (2014)

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
por: Klauck, Peter J., et al.
Publicado: (2018)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
por: Lieu, Christopher H., et al.
Publicado: (2015)

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
por: Pitts, Todd M., et al.
Publicado: (2016)

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer
por: Arcaroli, John, et al.
Publicado: (2012)

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
por: Davis, S. Lindsey, et al.
Publicado: (2015)

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy
por: Greene, Justin, et al.
Publicado: (2017)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
por: Capasso, Anna, et al.
Publicado: (2018)

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer
por: Davis, S. Lindsey, et al.
Publicado: (2018)

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models
por: Pitts, Todd M., et al.
Publicado: (2013)

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010)

Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling
por: Bieerkehazhi, Shayahati, et al.
Publicado: (2016)

Src and Abl hijack the Robo1 pathway
por: Naus, Christian
Publicado: (2010)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
por: XIAO, JUAN, et al.
Publicado: (2015)

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
por: Pitts, Todd M., et al.
Publicado: (2020)

Azithromycin is able to control Toxoplasma gondii infection in human villous explants
por: Castro-Filice, Letícia S, et al.
Publicado: (2014)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells
por: Dosch, Austin R., et al.
Publicado: (2019)

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
por: Gotesman, Moran, et al.
Publicado: (2018)

BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy
por: Yamada, Chika, et al.
Publicado: (2021)

WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
por: Hartman, Sarah J., et al.
Publicado: (2021)

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
por: Id Boufker, Hichame, et al.
Publicado: (2010)

Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling
por: WU, JIANGHONG, et al.
Publicado: (2013)

Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
por: Takiguchi, Eri, et al.
Publicado: (2017)

A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M, et al.
Publicado: (2006)

From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
por: Lieu, Christopher H., et al.
Publicado: (2013)

HOXC11–SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib
por: deBlacam, C, et al.
Publicado: (2011)

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma
por: Sun, Jingya, et al.
Publicado: (2018)

Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice
por: Lee, Dajeong, et al.
Publicado: (2020)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src kinases
por: Fernow, Inga, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_78jsq88furoqsg4fi9cl34o1d5